Core Viewpoint - The stock price of Berry Genomics has shown significant fluctuations, with a year-to-date increase of 55.15%, but a recent decline over the past 60 days of 10.45% [2][3]. Group 1: Stock Performance - As of October 31, Berry Genomics' stock price rose by 2.02% to 13.11 CNY per share, with a trading volume of 1.45 billion CNY and a market capitalization of 46.35 billion CNY [1]. - The stock has appeared on the trading leaderboard 8 times this year, with the most recent net buy of 22.37 million CNY on March 11 [2]. - The stock has experienced a 2.42% increase over the last 5 trading days and a 0.85% increase over the last 20 trading days [2]. Group 2: Financial Performance - For the period from January to September 2025, Berry Genomics reported a revenue of 686 million CNY, a year-on-year decrease of 16.65%, and a net profit loss of 52.56 million CNY, a decline of 606.13% [3]. - The company has not distributed any dividends in the last three years, with a total payout of 16.20 million CNY since its A-share listing [4]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 5.09% to 64,700, while the average number of circulating shares per person increased by 5.37% to 5,092 shares [3]. - The seventh largest circulating shareholder is a medical device ETF, which holds 1.5268 million shares as a new shareholder [4]. Group 4: Business Overview - Berry Genomics, established on April 14, 1997, specializes in high-throughput sequencing technology-based genetic testing, with its main revenue sources being reagent sales (45.74%), medical testing services (31.24%), and basic research services (18.33%) [2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and diagnostic services [2].

Core Insights - Berry Genomics is a leading company in the domestic gene sequencing field, established in April 1997 and listed on the Shenzhen Stock Exchange [1] Financial Performance - For Q3 2025, Berry Genomics reported revenue of 686 million yuan, ranking 5th in the industry, significantly lower than the top competitor, Dian Diagnostics, which had revenue of 7.566 billion yuan [2] - The revenue breakdown includes reagent sales at 205 million yuan (45.74%), medical testing services at 140 million yuan (31.24%), basic research services at 82.017 million yuan (18.33%), equipment sales at 15.562 million yuan (3.48%), and other services at 5.39 million yuan (1.20%) [2] - The net profit for the same period was -50.422 million yuan, ranking 4th in the industry, with the industry leader, Dian Diagnostics, reporting a net profit of 1.82 billion yuan [2] Financial Ratios - As of Q3 2025, Berry Genomics had a debt-to-asset ratio of 29.63%, which is lower than the industry average of 30.88% [3] - The gross profit margin for Q3 2025 was 47.75%, higher than the industry average of 35.76% [3] Executive Compensation - The chairman and general manager, Gao Yang, received a salary of 1.22 million yuan, a slight decrease from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 5.09% to 64,700, while the average number of circulating A-shares held per shareholder increased by 5.37% to 5,092.33 [5]